» Articles » PMID: 28984615

Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted Home Titration in Patients with Advanced Parkinson's Disease

Overview
Publisher Sage Publications
Specialty Neurology
Date 2017 Oct 7
PMID 28984615
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Levodopa-carbidopa intestinal gel (LCIG; Duodopa®) is used for continuous infusion in advanced Parkinson's disease. To achieve optimal effect, the LCIG dose is individually titrated, traditionally conducted during hospitalization in Sweden. However, dose adjustment depends on surrounding conditions, physical activity, and emotional stress, which is why titration at home could be beneficial. Telemedicine (TM) using a video communication system offers alternative titration procedures, allowing LCIG initiation at home.

Objective: Study objectives were to show the feasibility of TM for LCIG home titration, evaluate resource use, and assess patient, neurologist, and nurse satisfaction.

Methods: Four clinics enrolled 15 patients to observe efficiency and feasibility of TM-based monitoring.

Results: Patient median (range) age was 67 (52-73) years and time since diagnosis was 10 (7-23) years. Median time between LCIG initiation and end of TM-assisted titration was 2.8 (2.0-13.8) days. Median time required for home titration by neurologists, nurses, and patients was (hours:minutes) 1 : 14 (0 : 29-1 : 52), 5 : 49 (2 : 46-10 : 3), and 8 : 53 (4 : 11-14 : 11), respectively. Neurologists and nurses considered this to be less time than required for hospital titration. TM allowed patients 92% free time from start to end of titration. Technical problems associated with TM contacts were rare, mostly related to digital link, and quickly resolved. Patients, neurologists, and nurses were satisfied using TM. No serious adverse events were reported; there was one device complaint (tube occlusion).

Conclusions: In this study, TM-assisted LCIG titration at home was resource-efficient, technically feasible, well-accepted and was deemed satisfactory by patients, neurologists, and nurses.

Citing Articles

Satisfaction with videoconferencing support for levodopa-carbidopa intestinal gel: An observational study.

Gurevich T, Evans A, Hassin-Baer S, Kagi G, Koziorowski D, Roszmann A Digit Health. 2024; 10:20552076241271847.

PMID: 39224799 PMC: 11367587. DOI: 10.1177/20552076241271847.


Neurological Examination via Telemedicine: An Updated Review Focusing on Movement Disorders.

Angelopoulou E, Koros C, Stanitsa E, Stamelos I, Kontaxopoulou D, Fragkiadaki S Medicina (Kaunas). 2024; 60(6).

PMID: 38929575 PMC: 11205653. DOI: 10.3390/medicina60060958.


The role of nurses for patients with Parkinson's disease at home: a scoping review.

Fujita T, Iwaki M, Hatono Y BMC Nurs. 2024; 23(1):318.

PMID: 38730392 PMC: 11088224. DOI: 10.1186/s12912-024-01931-y.


Levodopa-Entacapone-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease: A Single Center Real-World Experience.

Szatmari S, Szasz J, Orban-Kis K, Baroti B, Bataga S, Ciorba M Pharmaceutics. 2024; 16(4).

PMID: 38675114 PMC: 11053778. DOI: 10.3390/pharmaceutics16040453.


Home-Based Titration with Duodenal Infusion of Levodopa-Carbidopa Intestinal Gel in People with Parkinson's Disease: An Observational Feasibility Study.

Thomsen T, Nielsen N, Isenberg A, Moller M, Clausen J, Schack Frederiksen I Parkinsons Dis. 2024; 2024:5522824.

PMID: 38623494 PMC: 11018374. DOI: 10.1155/2024/5522824.


References
1.
Palhagen S, Dizdar N, Hauge T, Holmberg B, Jansson R, Linder J . Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand. 2012; 126(6):e29-33. DOI: 10.1111/j.1600-0404.2012.01689.x. View

2.
Rubin M, Wellik K, Channer D, Demaerschalk B . Systematic review of teleneurology: methodology. Front Neurol. 2012; 3:156. PMC: 3497715. DOI: 10.3389/fneur.2012.00156. View

3.
Wechsler L . Advantages and limitations of teleneurology. JAMA Neurol. 2015; 72(3):349-54. DOI: 10.1001/jamaneurol.2014.3844. View

4.
Fernandez H, Vanagunas A, Odin P, Espay A, Hauser R, Standaert D . Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism Relat Disord. 2013; 19(3):339-45. PMC: 3661282. DOI: 10.1016/j.parkreldis.2012.11.020. View

5.
Antonini A, Yegin A, Preda C, Bergmann L, Poewe W . Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015; 21(3):231-5. DOI: 10.1016/j.parkreldis.2014.12.012. View